Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/730464/000115752322001521/a52959534.htm
May 2023
February 2023
November 2022
August 2022
June 2022
May 2022
May 2022
April 2022
![]() |
Investor Contact
Chandrika Nigam
Chandrika.Nigam@Adtalem.com
312-681-3209
Media Contact
Kelly Finelli
Kelly.Finelli@Adtalem.com
872-270-0230
|
●
|
Revenue of $354.6 million increased 22.7% compared with the prior year due to the timing of the acquisition of Walden
|
●
|
Diluted earnings per share increased to $0.05 from a loss of $1.17 in the prior year; adjusted earnings per share, increased to
$0.88 or by 151.4%, compared with $0.35 in the prior year
|
●
|
Operating income was $23.1 million, compared with an operating loss of $22.1 million in the prior year; adjusted operating
income was $65.1 million, an increase of 78.7% compared with the prior year. Operating margin was 6.5% and adjusted operating margin increased to 18.4% from 12.6% driven by integration and cost reduction efforts
|
●
|
Net income was $2.2 million, compared with a loss of $58.0 million in the prior year; adjusted net income was $41.0 million, an
increase of 133.1% compared with the prior year
|
●
|
Adjusted EBITDA was $82.1 million, an increase of 62.6% compared with the prior year. Adjusted EBITDA margins increased to 23.1%
from 17.5%
|
●
|
Gross debt was reduced by $101 million, representing a decrease of 11.7% in the first quarter
|
●
|
American University of the Caribbean School of Medicine and Ross
University School of Medicine established a partnership with Southern California University of Health Services to expand pathways to medicine for aspiring physicians
|
●
|
Ross University School of Medicine entered into a collaboration
with Bethune-Cookman University, a historically Black university, to create pathways for aspiring medical students, many of whom identify as a race or ethnicity underrepresented in medicine
|
●
|
Chamberlain University announced a transition agreement to
help recently displaced Stratford University nursing students continue their education and achieve their career ambitions
|
●
|
Adtalem’s FY 2019* combined cohort default rate remained well below combined cohort default rate for all schools nationally,
including public and not-for-profit four-year sectors, which is representative of the quality of our programs and the employability of our graduates.
|
Q1 2023
|
Q1 2022
|
% Change
|
||||||||||
Adtalem Global Education Student Enrollments
|
||||||||||||
Total students(1)
|
79,559
|
84,874
|
-6.3
|
%
|
||||||||
Chamberlain University
|
||||||||||||
Total students
|
33,153
|
34,539
|
-4.0
|
%
|
||||||||
Walden University
|
||||||||||||
Total students
|
40,772
|
44,886
|
-9.2
|
%
|
||||||||
Medical & Veterinary
|
||||||||||||
Total students
|
5,634
|
5,449
|
3.4
|
%
|
(1)
|
Represents total students attending sessions during each institution’s most recent enrollment period in Q1 FY 2023
and Q1 FY 2022
|
September 30,
|
June 30,
|
September 30,
|
||||||||||
2022
|
2022
|
2021
|
||||||||||
Assets:
|
||||||||||||
Current assets:
|
||||||||||||
Cash and cash equivalents
|
$
|
327,515
|
$
|
346,973
|
$
|
323,994
|
||||||
Restricted cash
|
2,480
|
964
|
20,220
|
|||||||||
Accounts receivable, net
|
111,858
|
81,635
|
140,390
|
|||||||||
Prepaid expenses and other current assets
|
128,069
|
126,467
|
162,463
|
|||||||||
Current assets held for sale
|
—
|
—
|
62,725
|
|||||||||
Total current assets
|
569,922
|
556,039
|
709,792
|
|||||||||
Noncurrent assets:
|
||||||||||||
Property and equipment, net
|
281,581
|
289,926
|
308,759
|
|||||||||
Operating lease assets
|
158,287
|
177,995
|
167,249
|
|||||||||
Deferred income taxes
|
49,318
|
51,093
|
61,654
|
|||||||||
Intangible assets, net
|
855,049
|
873,577
|
954,400
|
|||||||||
Goodwill
|
961,262
|
961,262
|
952,764
|
|||||||||
Other assets, net
|
120,630
|
119,283
|
113,819
|
|||||||||
Noncurrent assets held for sale
|
—
|
—
|
530,627
|
|||||||||
Total noncurrent assets
|
2,426,127
|
2,473,136
|
3,089,272
|
|||||||||
Total assets
|
$
|
2,996,049
|
$
|
3,029,175
|
$
|
3,799,064
|
||||||
Liabilities and shareholders' equity:
|
||||||||||||
Current liabilities:
|
||||||||||||
Accounts payable
|
$
|
64,407
|
$
|
57,140
|
$
|
99,691
|
||||||
Accrued payroll and benefits
|
55,034
|
66,642
|
57,463
|
|||||||||
Accrued liabilities
|
93,805
|
98,124
|
124,748
|
|||||||||
Deferred revenue
|
227,238
|
144,840
|
236,990
|
|||||||||
Current operating lease liabilities
|
50,065
|
50,781
|
55,925
|
|||||||||
Current portion of long-term debt
|
—
|
—
|
6,375
|
|||||||||
Current liabilities held for sale
|
—
|
—
|
55,038
|
|||||||||
Total current liabilities
|
490,549
|
417,527
|
636,230
|
|||||||||
Noncurrent liabilities:
|
||||||||||||
Long-term debt
|
741,696
|
838,908
|
1,600,043
|
|||||||||
Long-term operating lease liabilities
|
164,840
|
177,045
|
164,172
|
|||||||||
Deferred income taxes
|
26,408
|
25,554
|
26,390
|
|||||||||
Other liabilities
|
62,517
|
65,074
|
72,688
|
|||||||||
Noncurrent liabilities held for sale
|
—
|
—
|
32,570
|
|||||||||
Total noncurrent liabilities
|
995,461
|
1,106,581
|
1,895,863
|
|||||||||
Total liabilities
|
1,486,010
|
1,524,108
|
2,532,093
|
|||||||||
Commitments and contingencies
|
||||||||||||
Redeemable noncontrolling interest
|
—
|
—
|
1,790
|
|||||||||
Shareholders' equity:
|
||||||||||||
Common stock, $0.01 par value per share, 200,000 shares authorized; 45,396, 45,177, and 49,753 shares
outstanding as of September 30, 2022, June 30, 2022, and September 30, 2021, respectively
|
821
|
818
|
817
|
|||||||||
Additional paid-in capital
|
529,229
|
521,848
|
537,402
|
|||||||||
Retained earnings
|
2,325,002
|
2,322,810
|
1,947,101
|
|||||||||
Accumulated other comprehensive loss
|
(2,227
|
)
|
(960
|
)
|
(740
|
)
|
||||||
Treasury stock, at cost, 36,703, 36,619, and 31,903 shares as of September 30, 2022, June 30, 2022,
and September 30, 2021, respectively
|
(1,342,786
|
)
|
(1,339,449
|
)
|
(1,219,399
|
)
|
||||||
Total shareholders' equity
|
1,510,039
|
1,505,067
|
1,265,181
|
|||||||||
Total liabilities and shareholders' equity
|
$
|
2,996,049
|
$
|
3,029,175
|
$
|
3,799,064
|
Three Months Ended
|
||||||||
September 30,
|
||||||||
2022
|
2021
|
|||||||
Revenue
|
$
|
354,559
|
$
|
289,070
|
||||
Operating cost and expense:
|
||||||||
Cost of educational services
|
159,645
|
152,050
|
||||||
Student services and administrative expense
|
148,341
|
129,436
|
||||||
Restructuring expense
|
15,065
|
3,094
|
||||||
Business acquisition and integration expense
|
8,415
|
26,553
|
||||||
Total operating cost and expense
|
331,466
|
311,133
|
||||||
Operating income (loss)
|
23,093
|
(22,063
|
)
|
|||||
Other income (expense):
|
||||||||
Interest income
|
1,567
|
878
|
||||||
Interest expense
|
(17,760
|
)
|
(47,393
|
)
|
||||
Net other expense
|
(16,193
|
)
|
(46,515
|
)
|
||||
Income (loss) from continuing operations before income taxes
|
6,900
|
(68,578
|
)
|
|||||
Provision for income taxes
|
(1,054
|
)
|
(8,604
|
)
|
||||
Income (loss) from continuing operations
|
5,846
|
(77,182
|
)
|
|||||
Discontinued operations:
|
||||||||
Loss from discontinued operations before income taxes
|
(3,438
|
)
|
(6,050
|
)
|
||||
Loss on disposal of discontinued operations before income taxes
|
(3,359
|
)
|
—
|
|||||
Benefit from income taxes
|
3,143
|
25,228
|
||||||
(Loss) income from discontinued operations
|
(3,654
|
)
|
19,178
|
|||||
Net income (loss)
|
$
|
2,192
|
$
|
(58,004
|
)
|
|||
Earnings (loss) per share:
|
||||||||
Basic:
|
||||||||
Continuing operations
|
$
|
0.13
|
$
|
(1.55
|
)
|
|||
Discontinued operations
|
$
|
(0.08
|
)
|
$
|
0.39
|
|||
Total basic earnings (loss) per share
|
$
|
0.05
|
$
|
(1.17
|
)
|
|||
Diluted:
|
||||||||
Continuing operations
|
$
|
0.13
|
$
|
(1.55
|
)
|
|||
Discontinued operations
|
$
|
(0.08
|
)
|
$
|
0.39
|
|||
Total diluted earnings (loss) per share
|
$
|
0.05
|
$
|
(1.17
|
)
|
|||
Weighted-average shares outstanding:
|
||||||||
Basic shares
|
45,274
|
49,663
|
||||||
Diluted shares
|
46,342
|
49,663
|
Three Months Ended
|
||||||||
September 30,
|
||||||||
2022
|
2021
|
|||||||
Operating activities:
|
||||||||
Net income (loss)
|
$
|
2,192
|
$
|
(58,004
|
)
|
|||
Loss (income) from discontinued operations
|
3,654
|
(19,178
|
)
|
|||||
Income (loss) from continuing operations
|
5,846
|
(77,182
|
)
|
|||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
|
||||||||
Stock-based compensation expense
|
6,145
|
9,711
|
||||||
Amortization and impairments to operating lease assets
|
19,708
|
12,323
|
||||||
Depreciation
|
10,805
|
10,499
|
||||||
Amortization of intangible assets
|
18,528
|
16,451
|
||||||
Amortization and write-off of debt discount and issuance costs
|
4,227
|
17,858
|
||||||
Provision for bad debts
|
5,991
|
6,189
|
||||||
Deferred income taxes
|
2,629
|
(10,186
|
)
|
|||||
Loss on disposals, accelerated depreciation, and impairments to property and equipment
|
3,483
|
282
|
||||||
Gain on extinguishment of debt
|
(71
|
)
|
—
|
|||||
Changes in assets and liabilities:
|
||||||||
Accounts receivable
|
(33,219
|
)
|
(78,283
|
)
|
||||
Prepaid expenses and other current assets
|
(1,602
|
)
|
(199
|
)
|
||||
Accounts payable
|
7,586
|
26,706
|
||||||
Accrued payroll and benefits
|
(11,593
|
)
|
(21,231
|
)
|
||||
Accrued liabilities
|
(9,010
|
)
|
(24,846
|
)
|
||||
Deferred revenue
|
82,398
|
157,225
|
||||||
Operating lease liabilities
|
(12,921
|
)
|
(13,397
|
)
|
||||
Other assets and liabilities
|
(7,406
|
)
|
(2,414
|
)
|
||||
Net cash provided by operating activities-continuing operations
|
91,524
|
29,506
|
||||||
Net cash (used in) provided by operating activities-discontinued operations
|
(130
|
)
|
11,358
|
|||||
Net cash provided by operating activities
|
91,394
|
40,864
|
||||||
Investing activities:
|
||||||||
Capital expenditures
|
(5,551
|
)
|
(6,691
|
)
|
||||
Payment for purchase of business, net of cash and restricted cash acquired
|
—
|
(1,481,789
|
)
|
|||||
Net cash used in investing activities-continuing operations
|
(5,551
|
)
|
(1,488,480
|
)
|
||||
Net cash used in investing activities-discontinued operations
|
—
|
(633
|
)
|
|||||
Payment for working capital adjustment for sale of business
|
(811
|
)
|
—
|
|||||
Net cash used in investing activities
|
(6,362
|
)
|
(1,489,113
|
)
|
||||
Financing activities:
|
||||||||
Proceeds from exercise of stock options
|
1,241
|
7,685
|
||||||
Employee taxes paid on withholding shares
|
(3,486
|
)
|
(2,228
|
)
|
||||
Proceeds from stock issued under Colleague Stock Purchase Plan
|
132
|
114
|
||||||
Proceeds from long-term debt
|
—
|
850,000
|
||||||
Repayments of long-term debt
|
(100,861
|
)
|
(291,000
|
)
|
||||
Payment of debt discount and issuance costs
|
—
|
(49,553
|
)
|
|||||
Net cash (used in) provided by financing activities
|
(102,974
|
)
|
515,018
|
|||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
—
|
(70
|
)
|
|||||
Net decrease in cash, cash equivalents and restricted cash
|
(17,942
|
)
|
(933,301
|
)
|
||||
Cash, cash equivalents and restricted cash at beginning of period
|
347,937
|
1,313,616
|
||||||
Cash, cash equivalents and restricted cash at end of period
|
329,995
|
380,315
|
||||||
Less: cash, cash equivalents and restricted cash of discontinued operations at end of period
|
—
|
36,101
|
||||||
Cash, cash equivalents and restricted cash of continuing operations at end of period
|
$
|
329,995
|
$
|
344,214
|
||||
Non-cash investing and financing activities:
|
||||||||
Accrued capital expenditures
|
$
|
4,713
|
$
|
6,576
|
Three Months Ended
|
||||||||||||||||
September 30,
|
||||||||||||||||
Increase/(Decrease)
|
||||||||||||||||
2022
|
2021
|
$ |
|
%
|
||||||||||||
Revenue:
|
||||||||||||||||
Chamberlain
|
$
|
135,405
|
$
|
135,639
|
$
|
(234
|
)
|
(0.2
|
)%
|
|||||||
Walden
|
130,901
|
68,617
|
62,284
|
90.8
|
%
|
|||||||||||
Medical and Veterinary
|
88,253
|
84,814
|
3,439
|
4.1
|
%
|
|||||||||||
Total consolidated revenue
|
$
|
354,559
|
$
|
289,070
|
$
|
65,489
|
22.7
|
%
|
||||||||
Operating income (loss):
|
||||||||||||||||
Chamberlain
|
$
|
26,184
|
$
|
20,855
|
$
|
5,329
|
25.6
|
%
|
||||||||
Walden
|
1,783
|
(11,646
|
)
|
13,429
|
NM
|
|||||||||||
Medical and Veterinary
|
10,528
|
15,665
|
(5,137
|
)
|
(32.8
|
)%
|
||||||||||
Home Office and Other
|
(15,402
|
)
|
(46,937
|
)
|
31,535
|
67.2
|
%
|
|||||||||
Total consolidated operating income (loss)
|
$
|
23,093
|
$
|
(22,063
|
)
|
$
|
45,156
|
NM
|
●
|
Deferred revenue adjustment related to a revenue purchase accounting adjustment to record Walden’s deferred revenue at fair value.
|
●
|
CEO transition costs related to acceleration of stock-based compensation expense.
|
●
|
Restructuring expense primarily related to plans to achieve synergies with the Walden acquisition and real estate consolidations at Walden,
Medical and Veterinary, and Adtalem’s home office.
|
●
|
Business acquisition and integration expense include expenses related to the Walden acquisition and growth transformation initiatives.
|
●
|
Intangible amortization expense on acquired intangible assets.
|
●
|
Pre-acquisition interest expense, write-off of debt discount and issuance costs, and gain on extinguishment of debt related to financing
arrangements in connection with the Walden acquisition and prepayment of debt.
|
●
|
Net loss (income) from discontinued operations includes the operations of ACAMS, Becker, OCL, and EduPristine, in addition to costs related to
DeVry University.
|
Three Months Ended
|
||||||||||||||||
September 30,
|
||||||||||||||||
Increase/(Decrease)
|
||||||||||||||||
2022
|
2021
|
$ |
|
%
|
||||||||||||
Chamberlain:
|
||||||||||||||||
Operating income (GAAP)
|
$
|
26,184
|
$
|
20,855
|
$
|
5,329
|
25.6
|
%
|
||||||||
Restructuring expense
|
818
|
—
|
818
|
|||||||||||||
Adjusted operating income (non-GAAP)
|
$
|
27,002
|
$
|
20,855
|
$
|
6,147
|
29.5
|
%
|
||||||||
Operating margin (GAAP)
|
19.3
|
%
|
15.4
|
%
|
||||||||||||
Operating margin (non-GAAP)
|
19.9
|
%
|
15.4
|
%
|
||||||||||||
Walden:
|
||||||||||||||||
Operating income (loss) (GAAP)
|
$
|
1,783
|
$
|
(11,646
|
)
|
$
|
13,429
|
NM
|
||||||||
Deferred revenue adjustment
|
—
|
6,207
|
(6,207
|
)
|
||||||||||||
Restructuring expense
|
3,080
|
—
|
3,080
|
|||||||||||||
Intangible amortization expense
|
18,528
|
16,451
|
2,077
|
|||||||||||||
Adjusted operating income (non-GAAP)
|
$
|
23,391
|
$
|
11,012
|
$
|
12,379
|
112.4
|
%
|
||||||||
Operating margin (GAAP)
|
1.4
|
%
|
(17.0
|
)%
|
||||||||||||
Operating margin (non-GAAP)
|
17.9
|
%
|
16.0
|
%
|
||||||||||||
Medical and Veterinary:
|
||||||||||||||||
Operating income (GAAP)
|
$
|
10,528
|
$
|
15,665
|
$
|
(5,137
|
)
|
(32.8
|
)%
|
|||||||
Restructuring expense
|
6,826
|
—
|
6,826
|
|||||||||||||
Adjusted operating income (non-GAAP)
|
$
|
17,354
|
$
|
15,665
|
$
|
1,689
|
10.8
|
%
|
||||||||
Operating margin (GAAP)
|
11.9
|
%
|
18.5
|
%
|
||||||||||||
Operating margin (non-GAAP)
|
19.7
|
%
|
18.5
|
%
|
||||||||||||
Home Office and Other:
|
||||||||||||||||
Operating loss (GAAP)
|
$
|
(15,402
|
)
|
$
|
(46,937
|
)
|
$
|
31,535
|
67.2
|
%
|
||||||
CEO transition costs
|
—
|
6,195
|
(6,195
|
)
|
||||||||||||
Restructuring expense
|
4,341
|
3,094
|
1,247
|
|||||||||||||
Business acquisition and integration expense
|
8,415
|
26,553
|
(18,138
|
)
|
||||||||||||
Adjusted operating loss (non-GAAP)
|
$
|
(2,646
|
)
|
$
|
(11,095
|
)
|
$
|
8,449
|
76.2
|
%
|
||||||
Adtalem Global Education:
|
||||||||||||||||
Operating income (loss) (GAAP)
|
$
|
23,093
|
$
|
(22,063
|
)
|
$
|
45,156
|
NM
|
||||||||
Deferred revenue adjustment
|
—
|
6,207
|
(6,207
|
)
|
||||||||||||
CEO transition costs
|
—
|
6,195
|
(6,195
|
)
|
||||||||||||
Restructuring expense
|
15,065
|
3,094
|
11,971
|
|||||||||||||
Business acquisition and integration expense
|
8,415
|
26,553
|
(18,138
|
)
|
||||||||||||
Intangible amortization expense
|
18,528
|
16,451
|
2,077
|
|||||||||||||
Adjusted operating income (non-GAAP)
|
$
|
65,101
|
$
|
36,437
|
$
|
28,664
|
78.7
|
%
|
||||||||
Operating margin (GAAP)
|
6.5
|
%
|
(7.6
|
)%
|
||||||||||||
Operating margin (non-GAAP)
|
18.4
|
%
|
12.6
|
%
|
Three Months Ended
|
||||||||||||||||
September 30,
|
||||||||||||||||
Increase/(Decrease)
|
||||||||||||||||
2022
|
2021
|
$ |
|
%
|
||||||||||||
Chamberlain:
|
||||||||||||||||
Operating income (GAAP)
|
$
|
26,184
|
$
|
20,855
|
$
|
5,329
|
25.6
|
%
|
||||||||
Restructuring expense
|
818
|
—
|
818
|
|||||||||||||
Depreciation
|
4,481
|
4,584
|
(103
|
)
|
||||||||||||
Stock-based compensation
|
2,274
|
1,547
|
727
|
|||||||||||||
Adjusted EBITDA (non-GAAP)
|
$
|
33,757
|
$
|
26,986
|
$
|
6,771
|
25.1
|
%
|
||||||||
Adjusted EBITDA margin (non-GAAP)
|
24.9
|
%
|
19.9
|
%
|
||||||||||||
Walden:
|
||||||||||||||||
Operating income (loss) (GAAP)
|
$
|
1,783
|
$
|
(11,646
|
)
|
$
|
13,429
|
NM
|
||||||||
Deferred revenue adjustment
|
—
|
6,207
|
(6,207
|
)
|
||||||||||||
Restructuring expense
|
3,080
|
—
|
3,080
|
|||||||||||||
Intangible amortization expense
|
18,528
|
16,451
|
2,077
|
|||||||||||||
Depreciation
|
2,595
|
1,712
|
883
|
|||||||||||||
Stock-based compensation
|
1,905
|
707
|
1,198
|
|||||||||||||
Adjusted EBITDA (non-GAAP)
|
$
|
27,891
|
$
|
13,431
|
$
|
14,460
|
107.7
|
%
|
||||||||
Adjusted EBITDA margin (non-GAAP)
|
21.3
|
%
|
19.6
|
%
|
||||||||||||
Medical and Veterinary:
|
||||||||||||||||
Operating income (GAAP)
|
$
|
10,528
|
$
|
15,665
|
$
|
(5,137
|
)
|
(32.8
|
)%
|
|||||||
Restructuring expense
|
6,826
|
—
|
6,826
|
|||||||||||||
Depreciation
|
3,105
|
3,455
|
(350
|
)
|
||||||||||||
Stock-based compensation
|
1,475
|
928
|
547
|
|||||||||||||
Adjusted EBITDA (non-GAAP)
|
$
|
21,934
|
$
|
20,048
|
$
|
1,886
|
9.4
|
%
|
||||||||
Adjusted EBITDA margin (non-GAAP)
|
24.9
|
%
|
23.6
|
%
|
||||||||||||
Home Office and Other:
|
||||||||||||||||
Operating loss (GAAP)
|
$
|
(15,402
|
)
|
$
|
(46,937
|
)
|
$
|
31,535
|
67.2
|
%
|
||||||
CEO transition costs
|
—
|
6,195
|
(6,195
|
)
|
||||||||||||
Restructuring expense
|
4,341
|
3,094
|
1,247
|
|||||||||||||
Business acquisition and integration expense
|
8,415
|
26,553
|
(18,138
|
)
|
||||||||||||
Depreciation
|
624
|
748
|
(124
|
)
|
||||||||||||
Stock-based compensation
|
491
|
334
|
157
|
|||||||||||||
Adjusted EBITDA (non-GAAP)
|
$
|
(1,531
|
)
|
$
|
(10,013
|
)
|
$
|
8,482
|
84.7
|
%
|
||||||
Adtalem Global Education:
|
||||||||||||||||
Net income (loss) (GAAP)
|
$
|
2,192
|
$
|
(58,004
|
)
|
$
|
60,196
|
NM
|
||||||||
Net loss (income) from discontinued operations
|
3,654
|
(19,178
|
)
|
22,832
|
||||||||||||
Net other expense
|
16,193
|
46,515
|
(30,322
|
)
|
||||||||||||
Provision for income taxes
|
1,054
|
8,604
|
(7,550
|
)
|
||||||||||||
Operating income (loss) (GAAP)
|
23,093
|
(22,063
|
)
|
45,156
|
||||||||||||
Depreciation and amortization
|
29,333
|
26,950
|
2,383
|
|||||||||||||
Stock-based compensation
|
6,145
|
3,516
|
2,629
|
|||||||||||||
Deferred revenue adjustment
|
—
|
6,207
|
(6,207
|
)
|
||||||||||||
CEO transition costs
|
—
|
6,195
|
(6,195
|
)
|
||||||||||||
Restructuring expense
|
15,065
|
3,094
|
11,971
|
|||||||||||||
Business acquisition and integration expense
|
8,415
|
26,553
|
(18,138
|
)
|
||||||||||||
Adjusted EBITDA (non-GAAP)
|
$
|
82,051
|
$
|
50,452
|
$
|
31,599
|
62.6
|
%
|
||||||||
Adjusted EBITDA margin (non-GAAP)
|
23.1
|
%
|
17.5
|
%
|
Three Months Ended
|
||||||||
September 30,
|
||||||||
2022
|
2021
|
|||||||
Net income (loss) (GAAP)
|
$
|
2,192
|
$
|
(58,004
|
)
|
|||
Deferred revenue adjustment
|
—
|
6,207
|
||||||
CEO transition costs
|
—
|
6,195
|
||||||
Restructuring expense
|
15,065
|
3,094
|
||||||
Business acquisition and integration expense
|
8,415
|
26,553
|
||||||
Intangible amortization expense
|
18,528
|
16,451
|
||||||
Pre-acquisition interest expense, write-off of debt discount and issuance costs, and gain on extinguishment of debt
|
2,824
|
31,634
|
||||||
Income tax impact on non-GAAP adjustments (1)
|
(9,673
|
)
|
4,640
|
|||||
Net loss (income) from discontinued operations
|
3,654
|
(19,178
|
)
|
|||||
Adjusted net income (non-GAAP)
|
$
|
41,005
|
$
|
17,592
|
Three Months Ended
|
||||||||
September 30,
|
||||||||
2022
|
2021
|
|||||||
Earnings (loss) per share, diluted (GAAP)
|
$
|
0.05
|
$
|
(1.17
|
)
|
|||
Effect on diluted earnings per share:
|
||||||||
Deferred revenue adjustment
|
-
|
0.12
|
||||||
CEO transition costs
|
-
|
0.12
|
||||||
Restructuring expense
|
0.33
|
0.06
|
||||||
Business acquisition and integration expense
|
0.18
|
0.53
|
||||||
Intangible amortization expense
|
0.40
|
0.33
|
||||||
Pre-acquisition interest expense, write-off of debt discount and issuance costs, and gain on extinguishment of
debt
|
0.06
|
0.63
|
||||||
Income tax impact on non-GAAP adjustments (1)
|
(0.21
|
)
|
0.09
|
|||||
Net loss (income) from discontinued operations
|
0.08
|
(0.39
|
)
|
|||||
Adjusted earnings per share, diluted (non-GAAP)
|
$
|
0.88
|
$
|
0.35
|
||||
Diluted shares used in non-GAAP EPS calculation
|
46,342
|
50,222
|
Three Months Ended
|
Twelve Months Ended
|
||||||||||||||||||||||||
FY23
|
FY22
|
FY23
|
FY22
|
FY22
|
FY22
|
FY22
|
FY21
|
||||||||||||||||||
|
Q1
|
|
Q1
|
|
Q1
|
Q4
|
Q3
|
Q2
|
Q1
|
Q4
|
|||||||||||||||
Net cash provided by operating activities-
continuing operations (GAAP)
|
$
|
91,524
|
$
|
29,506
|
$
|
225,843
|
$
|
163,825
|
$
|
101,481
|
$
|
91,835
|
$
|
124,742
|
$
|
168,760
|
|||||||||
Capital expenditures
|
(5,551)
|
(6,691)
|
(29,914)
|
(31,054)
|
(33,539)
|
(34,949)
|
(34,256)
|
(39,881)
|
|||||||||||||||||
Free cash flow (non-GAAP)
|
$
|
85,973
|
$
|
22,815
|
$
|
195,929
|
$
|
132,771
|
$
|
67,942
|
$
|
56,886
|
$
|
90,486
|
$
|
128,879
|
Year Ended
|
|||
June 30, 2023
|
|||
Expected earnings per share, diluted (GAAP)
|
$
|
2.05 to 2.30
|
|
Expected effects on diluted earnings per share:
|
|||
Restructuring expense
|
0.33
|
||
Integration costs
|
0.18
|
||
Estimated purchase accounting adjustment - intangible amortization
|
1.32
|
||
Write-off of debt discount and issuance costs and gain on extinguishment of debt
|
0.06
|
||
Estimated incremental integration costs
|
0.56
|
||
Estimated income tax impact on non-GAAP adjustments(1)
|
(0.63)
|
||
Net loss from discontinued operations
|
0.08
|
||
Expected adjusted earnings per share, diluted (non-GAAP)(2)
|
$
|
3.95 to 4.20
|
|
Diluted shares used in EPS calculation
|
46,342
|
Twelve Months Ended
|
||||
|
September 30, 2022 |
|||
Adtalem Global Education:
|
||||
Net income (GAAP)
|
$
|
377,901
|
||
Net income from discontinued operations
|
(324,700
|
)
|
||
Net other expense
|
95,206
|
|||
Benefit from income taxes
|
(22,787
|
)
|
||
Depreciation and amortization
|
144,231
|
|||
Stock-based compensation
|
19,045
|
|||
Deferred revenue adjustment
|
2,354
|
|||
Restructuring expense
|
37,599
|
|||
Business acquisition and integration expense
|
35,060
|
|||
Adjusted EBITDA (non-GAAP)
|
$
|
363,909
|
||
|
September 30, 2022 | |||
Long-term debt
|
$
|
758,283
|
||
Less: Cash and cash equivalents
|
(327,515
|
)
|
||
Net debt (non-GAAP)
|
$
|
430,768
|
||
Net leverage (non-GAAP)
|
1.2
|
x
|
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/730464/000115752322001521/a52959534.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Adtalem Global Education Inc..
Adtalem Global Education Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Material Contracts, Statements, Certifications & more
Adtalem Global Education Inc. provided additional information to their SEC Filing as exhibits
Ticker: ATGEEvents:
CIK: 730464
Form Type: 8-K Corporate News
Accession Number: 0001157523-22-001521
Submitted to the SEC: Thu Nov 03 2022 4:06:49 PM EST
Accepted by the SEC: Thu Nov 03 2022
Period: Thursday, November 3, 2022
Industry: Educational Services